Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Isocell S A S is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being handled by 1 distinct examiner, JONES-FOSTER, ERICA NICOLE. The presence of only 1 pending office action indicates that the company's current prosecution activity is concentrated on a single application. This allows for a focused approach to the specific examination requirements of 1 individual.
The pending matter is located within 1 distinct art unit. This suggests that the technical subject matter of the 1 pending office action is categorized within a specific niche of the Biotechnology & Pharmaceuticals field. The individual identified as the busiest examiner for the portfolio is the only examiner currently assigned to a pending case. This person is responsible for 1 pending office action.
Because the total number of pending office actions is 1, JONES-FOSTER, ERICA NICOLE manages the company's entire current pending workload. Practitioners should focus their strategy on the specific feedback provided by this 1 distinct examiner. The alignment of 1 distinct art unit and 1 distinct examiner represents a highly centralized prosecution path for the company at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838671 | USE OF SUPEROXIDE DISMUTASE FOR THE TREATMENT AND/OR PREVENTION OF ALLERGIC ASTHMA | JONES-FOSTER, ERICA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838671 | USE OF SUPEROXIDE DISMUTASE FOR THE TREATMENT AND/OR PREVENTION OF ALLERGIC ASTHMA | JONES-FOSTER, ERICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838671 | USE OF SUPEROXIDE DISMUTASE FOR THE TREATMENT AND/OR PREVENTION OF ALLERGIC ASTHMA | JONES-FOSTER, ERICA NICOLE | 1656 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIsocell S A S has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erica Nicole Jones-Foster has the most, with 1 of Isocell S A S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
